Workshop: Accelerating Medical Product Development in Kidney Transplantation Through a Public-private Partnership
C-Path’s Transplant Therapeutics Consortium (TTC), in collaboration with key opinion leaders from academic institutions, the pharmaceutical and diagnostic industries, FDA, and the patient community, is excited to host an upcoming public workshop, “Accelerating medical product development in kidney transplantation through a public-private partnership” to be held virtually, September 22, 8 a.m. to 12 p.m. ET.
The workshop will cover the qualification process of a composite surrogate for long-term graft loss after kidney transplantation, use of real-world evidence (RWE) in transplant clinical trials, and future endpoints in kidney transplantation.
This public workshop will focus on 1) qualifying a composite surrogate for long-term graft loss after kidney transplantation 2) real-world evidence use in transplant clinical trials and 3) potential future endpoints in kidney transplantation
TTC aims to accelerate the medical product development process for transplantation by identifying challenges, prioritizing solutions, and developing tools to advance new product development to meet the most pressing needs of transplant recipients.
|Session 1: Qualifying a composite surrogate for long-term graft loss after kidney transplantation
|Session 2: RWE use in transplant clinical trials
|Session 3: Future endpoints in kidney transplantation
Critical Path Institute is supported by the Food and Drug Administration (FDA) of the U.S. Department of Health and Human Services (HHS) and is 54.2% funded by the FDA/HHS, totaling $13,239,950, and 45.8% funded by non-government source(s), totaling $11,196,634. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, FDA/HHS or the U.S. Government.